MC1R
Melanocyte-stimulating hormone receptor
As of the edition of 20 October 2026, MC1R (melanocyte-stimulating hormone receptor, UniProt Q01726) has 3 drugs tested at it and 4 companies on the list, 2 on route A and 1 on route B.
Sources: UniProt, ClinicalTrials.gov, ChEMBL, FDA Orange Book and Purple Book, Pharos.
The protein
- UniProt
- Q01726
- How well studied
- Drug target: an approved drug acts on it
- Where it sits in the cell
- At a membrane
- Solved structures
- 5
- Disease areas
- Skin and connective tissue; Inherited and neonatal; Nutrition and metabolism; Digestive system; Pregnancy and women's health; Urinary and reproductive; Cancer; Immune system
- Registered trials of its drugs
- 39
Drugs at this target
| Status | Count |
|---|---|
| Marketed | 1 |
| Active | 1 |
| Stopped | 1 |
| Total | 3 |
| Drug | Status | Furthest phase | US protection |
|---|---|---|---|
| Afamelanotide | Marketed | Phase 3 | Ended 2026 |
| Dersimelagon | Active | Phase 3 | none listed |
| Modimelanotide | Stopped | Phase 2 | none listed |
3 of 3 drugs, the most tested first.
Companies at this target
| Where the company stands | Companies |
|---|---|
| Route A | 2 |
| Route B | 1 |
| Engaged | 1 |
| Total on the list | 4 |
| Company | Route |
|---|---|
| AbbVie | Route A |
| Clinuvel | Route B |
| Action Pharma A/S | Route A |
The other 1 company at MC1R
In the product4 companies in all; 1 is not named here, and no score is.
See the 4 companies at MC1R, ranked, with the facts behind eachRequest access. Nothing is shown until you do.